Janneke Anink

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis

Janneke Anink, Lisette W. A. van Suijlekom‐Smit, M.H. Otten et al. · Arthritis Research & Therapy · 2015 · 77 citations · Full text

Immunology, Pathology, Psoriatic Arthritis +17

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register

M.H. Otten, Femke H. M. Prince, Janneke Anink et al. · Annals of the Rheumatic Diseases · 2012 · 57 citations · Full text

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register

M.H. Otten, Janneke Anink, Femke H. M. Prince et al. · Annals of the Rheumatic Diseases · 2014 · 55 citations

Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register

Janneke Anink, Femke H. M. Prince, Maryanne Dijkstra et al. · Lara D. Veeken · 2015 · 42 citations · Full text

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Janneke Anink, M.H. Otten, Simone Gorter et al. · Lara D. Veeken · 2013 · 39 citations · Full text